<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35241645</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-3635</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Signal transduction and targeted therapy</Title><ISOAbbreviation>Signal Transduct Target Ther</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates.</ArticleTitle><Pagination><StartPage>69</StartPage><MedlinePgn>69</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">69</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41392-022-00926-y</ELocationID><Abstract><AbstractText>Emerging SARS-CoV-2 variants and the gradually decreasing neutralizing antibodies over time post vaccination have led to an increase in incidents of breakthrough infection across the world. To investigate the potential protective effect of the recombinant protein subunit COVID-19 vaccine targeting receptor-binding domain (RBD) (PS-RBD) and whole inactivated virus particle vaccine (IV) against the variant strains, in this study, rhesus macaques were immunized with PS-RBD or IV vaccine, followed by a Beta variant (B.1.351) challenge. Although neutralizing activity against the Beta variant was reduced compared with that against the prototype, the decreased viral load in both upper and lower respiratory tracts, milder pathological changes, and downregulated inflammatory cytokine levels in lung tissues after challenge demonstrated that PS-RBD and IV still provided effective protection against the Beta variant in the macaque model. Furthermore, PS-RBD-induced macaque sera possessed general binding and neutralizing activity to Alpha, Beta, Delta, and Omicron variants in our study, though the neutralizing antibody (NAb) titers declined by varying degrees, demonstrating potential protection of PS-RBD against current circulating variants of concern (VOCs). Interestingly, although the IV vaccine-induced extremely low neutralizing antibody titers against the Beta variant, it still showed reduction for viral load and significantly alleviated pathological change. Other correlates of vaccine-induced protection (CoP) like antibody-dependent cellular cytotoxicity (ADCC) and immune memory were both confirmed to be existing in IV vaccinated group and possibly be involved in the protective mechanism.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Peng</LastName><ForeName>Xiaozhong</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-8564-0247</Identifier><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Sciences &amp; Peking Union Medical College, Kunming, 650118, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>He</LastName><ForeName>Zhanlong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Sciences &amp; Peking Union Medical College, Kunming, 650118, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lu</LastName><ForeName>Shuaiyao</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1675-9735</Identifier><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Sciences &amp; Peking Union Medical College, Kunming, 650118, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jialu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Lianlian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Chaoqiang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Wenhai</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Sciences &amp; Peking Union Medical College, Kunming, 650118, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fengmei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Sciences &amp; Peking Union Medical College, Kunming, 650118, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yanan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Sciences &amp; Peking Union Medical College, Kunming, 650118, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Sciences &amp; Peking Union Medical College, Kunming, 650118, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yanyan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Sciences &amp; Peking Union Medical College, Kunming, 650118, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Yadi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Xujia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jinghuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Weijin</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-4246-8889</Identifier><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Changgui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junzhi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China. wangjz@nifdc.org.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China. lzhenglun@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, 102629, People's Republic of China. xumiaobj@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Signal Transduct Target Ther</MedlineTA><NlmUniqueID>101676423</NlmUniqueID><ISSNLinking>2059-3635</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35241645</ArticleId><ArticleId IdType="pmc">PMC8892123</ArticleId><ArticleId IdType="doi">10.1038/s41392-022-00926-y</ArticleId><ArticleId IdType="pii">10.1038/s41392-022-00926-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO. Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process, 2021).</Citation></Reference><Reference><Citation>WHO. WHO Coronavirus (COVID-19) Dashboard, 2021).</Citation></Reference><Reference><Citation>Data, O. W. I. Weekly confirmed COVID-19 cases, 2021).</Citation></Reference><Reference><Citation>Davies NG, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:eabg3055. doi: 10.1126/science.abg3055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg3055</ArticleId><ArticleId IdType="pmc">PMC8128288</ArticleId><ArticleId IdType="pubmed">33658326</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally H, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592:438–443. doi: 10.1038/s41586-021-03402-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03402-9</ArticleId><ArticleId IdType="pubmed">33690265</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria NR, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372:815–821. doi: 10.1126/science.abh2644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh2644</ArticleId><ArticleId IdType="pmc">PMC8139423</ArticleId><ArticleId IdType="pubmed">33853970</ArticleId></ArticleIdList></Reference><Reference><Citation>PH, E. SARS-CoV-2 variants of concern and variants under investigation in England.</Citation></Reference><Reference><Citation>Davies NG, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593:270–274. doi: 10.1038/s41586-021-03426-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03426-1</ArticleId><ArticleId IdType="pmc">PMC9170116</ArticleId><ArticleId IdType="pubmed">33723411</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk T. P. A., Spiteri G., Bundle N., Melidou A., Carr M. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8063589</ArticleId><ArticleId IdType="pubmed">33890566</ArticleId></ArticleIdList></Reference><Reference><Citation>CA, P. Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y.V2.</Citation></Reference><Reference><Citation>Collier DA, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593:136–141. doi: 10.1038/s41586-021-03412-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03412-7</ArticleId><ArticleId IdType="pubmed">33706364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jangra S, et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe. 2021;2:e283–e284. doi: 10.1016/S2666-5247(21)00068-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00068-9</ArticleId><ArticleId IdType="pmc">PMC8026167</ArticleId><ArticleId IdType="pubmed">33846703</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593:142–146. doi: 10.1038/s41586-021-03471-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03471-w</ArticleId><ArticleId IdType="pmc">PMC9867906</ArticleId><ArticleId IdType="pubmed">33780970</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184:2348–2361. doi: 10.1016/j.cell.2021.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.037</ArticleId><ArticleId IdType="pmc">PMC7901269</ArticleId><ArticleId IdType="pubmed">33730597</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Tracking SARS-CoV-2 variants, 2021).</Citation></Reference><Reference><Citation>Madhi SA, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N. Engl. J. Med. 2021;384:1885–1898. doi: 10.1056/NEJMoa2102214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102214</ArticleId><ArticleId IdType="pmc">PMC7993410</ArticleId><ArticleId IdType="pubmed">33725432</ArticleId></ArticleIdList></Reference><Reference><Citation>Edara VV, et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe. 2021;29:516–521. doi: 10.1016/j.chom.2021.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.03.009</ArticleId><ArticleId IdType="pmc">PMC7980225</ArticleId><ArticleId IdType="pubmed">33798491</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates TA, et al. Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. Nat. Commun. 2021;12:5135. doi: 10.1038/s41467-021-25479-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25479-6</ArticleId><ArticleId IdType="pmc">PMC8390486</ArticleId><ArticleId IdType="pubmed">34446720</ArticleId></ArticleIdList></Reference><Reference><Citation>Edara, V. V. et al. Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant. Preprint at bioRxiv10.1101/2021.02.20.432046 (2021).</Citation></Reference><Reference><Citation>Wall EC, et al. AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. Lancet. 2021;398:207–209. doi: 10.1016/S0140-6736(21)01462-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01462-8</ArticleId><ArticleId IdType="pmc">PMC8238446</ArticleId><ArticleId IdType="pubmed">34197809</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596:273–275. doi: 10.1038/s41586-021-03693-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03693-y</ArticleId><ArticleId IdType="pubmed">34111888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall EC, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397:2331–2333. doi: 10.1016/S0140-6736(21)01290-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01290-3</ArticleId><ArticleId IdType="pmc">PMC8175044</ArticleId><ArticleId IdType="pubmed">34090624</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–280. doi: 10.1038/s41586-021-03777-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03777-9</ArticleId><ArticleId IdType="pubmed">34237773</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 2021;385:585–594. doi: 10.1056/NEJMoa2108891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108891</ArticleId><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro, J. et al. Efficacy estimates for various COVID-19 vaccines: what we know from the literature and reports. Preprint at medRxiv10.1101/2021.05.20.21257461 (2021).</Citation></Reference><Reference><Citation>WHO. COVID-19 Vaccine Tracker and Landscape (2021).</Citation></Reference><Reference><Citation>Yang S, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis. 2021;21:1107–1119. doi: 10.1016/S1473-3099(21)00127-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00127-4</ArticleId><ArticleId IdType="pmc">PMC7990482</ArticleId><ArticleId IdType="pubmed">33773111</ArticleId></ArticleIdList></Reference><Reference><Citation>Staff. Zifivax (ZF2001) COVID-19 Vaccine (2021).</Citation></Reference><Reference><Citation>Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 2012;12:557–569. doi: 10.1038/nri3254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3254</ArticleId><ArticleId IdType="pubmed">22790179</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 2021;29:529–539. doi: 10.1016/j.chom.2021.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.03.002</ArticleId><ArticleId IdType="pmc">PMC7934674</ArticleId><ArticleId IdType="pubmed">33705729</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021;29:747–751. doi: 10.1016/j.chom.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8053237</ArticleId><ArticleId IdType="pubmed">33887205</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan, J. et al. Structural and computational insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction. Preprint at bioRxiv10.1101/2022.01.03.474855 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9007263</ArticleId><ArticleId IdType="pubmed">35418218</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WB, et al. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies. J. Mol. Graph. Model. 2021;109:108035. doi: 10.1016/j.jmgm.2021.108035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmgm.2021.108035</ArticleId><ArticleId IdType="pmc">PMC8447841</ArticleId><ArticleId IdType="pubmed">34562851</ArticleId></ArticleIdList></Reference><Reference><Citation>Jangra S, et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe. 2021;2:e283–e284. doi: 10.1016/S2666-5247(21)00068-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00068-9</ArticleId><ArticleId IdType="pmc">PMC8026167</ArticleId><ArticleId IdType="pubmed">33846703</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S, et al. Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduct. Target Ther. 2020;5:157. doi: 10.1038/s41392-020-00269-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00269-6</ArticleId><ArticleId IdType="pmc">PMC7434851</ArticleId><ArticleId IdType="pubmed">32814760</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan C, et al. Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques. Cell Res. 2020;30:670–677. doi: 10.1038/s41422-020-0364-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0364-z</ArticleId><ArticleId IdType="pmc">PMC7364749</ArticleId><ArticleId IdType="pubmed">32636454</ArticleId></ArticleIdList></Reference><Reference><Citation>Salguero FJ, et al. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. Nat. Commun. 2021;12:1260. doi: 10.1038/s41467-021-21389-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21389-9</ArticleId><ArticleId IdType="pmc">PMC7904795</ArticleId><ArticleId IdType="pubmed">33627662</ArticleId></ArticleIdList></Reference><Reference><Citation>CDE. Technical Points for Non-clinical Studies and Evaluation of Prophylactic COVID-19 Vaccines (Trial edition) (2020).</Citation></Reference><Reference><Citation>Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 2020;130:2620–2629. doi: 10.1172/JCI137244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102763</ArticleId><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590:630–634. doi: 10.1038/s41586-020-03041-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03041-6</ArticleId><ArticleId IdType="pmc">PMC7906955</ArticleId><ArticleId IdType="pubmed">33276369</ArticleId></ArticleIdList></Reference><Reference><Citation>Grudzien M, Rapak A. Effect of Natural Compounds on NK Cell Activation. J. Immunol. Res. 2018;2018:4868417. doi: 10.1155/2018/4868417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/4868417</ArticleId><ArticleId IdType="pmc">PMC6323526</ArticleId><ArticleId IdType="pubmed">30671486</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunn BM, et al. A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola Virus. Cell Host Microbe. 2018;24:221–233. doi: 10.1016/j.chom.2018.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2018.07.009</ArticleId><ArticleId IdType="pmc">PMC6298217</ArticleId><ArticleId IdType="pubmed">30092199</ArticleId></ArticleIdList></Reference><Reference><Citation>Terajima M, Co MD, Cruz J, Ennis FA. High antibody-dependent cellular cytotoxicity antibody titers to H5N1 and H7N9 avian influenza A viruses in healthy US adults and older children. J. Infect. Dis. 2015;212:1052–1060. doi: 10.1093/infdis/jiv181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiv181</ArticleId><ArticleId IdType="pmc">PMC4668882</ArticleId><ArticleId IdType="pubmed">25795791</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderven HA, Kent SJ. The protective potential of Fc-mediated antibody functions against influenza virus and other viral pathogens. Immunol. Cell Biol. 2020;98:253–263. doi: 10.1111/imcb.12312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imcb.12312</ArticleId><ArticleId IdType="pubmed">31914207</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, et al. Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. Signal Transduct. Target Ther. 2021;6:346. doi: 10.1038/s41392-021-00759-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00759-1</ArticleId><ArticleId IdType="pmc">PMC8463587</ArticleId><ArticleId IdType="pubmed">34561414</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 2020;9:680–686. doi: 10.1080/22221751.2020.1743767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1743767</ArticleId><ArticleId IdType="pmc">PMC7144318</ArticleId><ArticleId IdType="pubmed">32207377</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J, et al. Development of an antibody-dependent cellular cytotoxicity reporter assay for measuring anti-Middle East Respiratory Syndrome antibody bioactivity. Sci. Rep. 2020;10:16615. doi: 10.1038/s41598-020-73960-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-73960-x</ArticleId><ArticleId IdType="pmc">PMC7538987</ArticleId><ArticleId IdType="pubmed">33024203</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4:e123158. doi: 10.1172/jci.insight.123158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.123158</ArticleId><ArticleId IdType="pmc">PMC6478436</ArticleId><ArticleId IdType="pubmed">30830861</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>